Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
CNBC Markets · Thu, 29 Oct 2026 10:56:02 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.”
Rule-based headline sentiment: Bullish
More Stocks headlines
DoorDash to acquire Instacart for $17 billion— CNBC MarketsInside the scramble that moved Thursday's WNBA Finals game to 12:30 p.m. ET— CNBC MarketsWeil, Gotshal & Manges, longtime Wall Street law firm, plans wind down— CNBC MarketsWe’re adding to our position in a rebounding bank stock— CNBC Markets
New to the fundamentals behind stories like this?
OmniFin Academy covers money basics, risk management, and reading markets — free, self-paced, no sign-up required.
Start OmniFin Academy →